Eosinophils and atopic dermatitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 59, Issue 6, 2004, Pages 561-570

  Simon, D ^a   Braathen, L R ^a   Simon, H U ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Atopic dermatitis; Eosinophils; Eotaxin; Inflammation; Interleukin 5

Indexed keywords

CYCLOSPORIN; CYTOKINE; GLUCOCORTICOID; INTERLEUKIN 5 ANTIBODY; MAJOR BASIC PROTEIN; TACROLIMUS;

APOPTOSIS; ASTHMA; ATOPIC DERMATITIS; CELL ACTIVATION; CELL INFILTRATION; CHEMOTAXIS; EOSINOPHIL; HELPER CELL; HUMAN; IMMUNOREGULATION; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN DEFECT; WELLS SYNDROME;

CHEMOKINES, CC; CYTOKINES; DERMATITIS, ATOPIC; EOSINOPHILS; HUMANS; INTERLEUKIN-5; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 2942608985     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2004.00476.x     Document Type: Review

References (116)

1. KATO M, KEPHART GM, TALLEY NJ, WAGNER JM, SARR MG, BONNO M et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998;252:418-425.
2. STRAUMANN A, SIMON HU. The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy 2004;59:15-25.
3. MIHM MC, SOTER NA, DVORAK HF, AUSTEN KF. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976;67: 305-312.
4. STEIGLEDER GK, INDERWISCH R. Eosinophilic leucocytes in the skin lesions of psoriais and atopic dermatitis. Arch Dermatol Res 1975;254:253-255.
5. BRAUN-FALCO O, BURG G. Celluläres infiltrat und Capillaren bei Neurodermitis diffusa. Arch Derm Forsch 1974;249:113-124.
6. KIEHL P, FALKENBERG K, VOGELBRUCH M, KAPP A. Tissue eosinophilia in acute and chronic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 2001;145:720-729.
7. SPERGEL JM, MIZOGUCHI E, OETTGEN H, BHAN AK, GEHA RS. Roles of Th1 and Th2 cytokines in a murine model of allergic dermatitis. J Clin Invest 1999;103:1103-1111.
8. KAGI MK, JOLLER-JEMELKA H, WÜTHRICH B. Correlation of eosinophils, eosinophilic cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology 1992;185:88-92.
9. UEHARA M, IZUKURA R, SAWAI T. Blood eosinophilia in atopic dermatitis. Clin Exp Dermatol 1990;15:264-266.
10. AKDIS CA, AKDIS M, SIMON D, DIBBERT B, WEBER M, GRATZL S et al. T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 1999;113:628-634.
11. SUR S, GLITZ DG, KITA H, KUJAWA SM, PETERSON EA, WEILER DA et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol 1998;63:715-722.
12. CZECH W, KRUTMANN J, SCHOPF E, KAPP A. Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. Br J Dermatol 1992;126:351-355.
13. HALMERBAUER G, FRISCHER T, KOLLER DY. Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. Allergy 1997;52:765-769.
14. TANIUCHI S, CHIHARA J, KOJIMA T, YAMAMOTO A, SASAI M, KOBAYASHI Y. Serum eosinophil derived neurotoxin may reflect more strongly disease activity in childhood atopic dermatitis than eosinophil cationic protein. J Dermatol Sci 2001;26:79-82.
15. CAPRONI M, AGATA AD, CAPPELLI G, FABBRI P. Modulation of serum eosinophilic cationic protein levels by cyclosporin in severe atopic dermatitis. Br J Dermatol 1996;135:336.
16. STEVENS SR, HANIFIN JM, HAMILTON T, TOFTE SJ, COOPER KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998;134:799-804.
17. WALKER C, KAGI MK, INGOLD P, BRAUN P, BLASER K, BRUIJNZEEL-KOOMEN CA et al. Atopic dermatitis: correlation of peripheral blood T cell activation, eosinophilia and serum factors with clinical severity. Clin Exp Allergy 1993;23:145-153.
18. KRUTMANN J, CZECH W, DIEPGEN T, NIEDNER R, KAPP A, SCHOPF E. High-dose UV A1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992;26:225-230.
19. KIM TY, PARK HJ, KIM CW. Eosinophil cationic protein (ECP) level and its correlation with eosinophil number or IgE level of peripheral blood in patients with various skin diseases. J Dermatol Sci 1997;15:89-94.
20. WASSOM DL, LOEGERING DA, SOLLEY GO, MOORE SB, SCHOOLEY RT, FAUCI AS et al. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest 1981;67:651-661.
21. TISCHENDORF FW, BRATTIG NW, LINTZEL M, BUTTNER DW, BURCHARD GD, BORK K et al. Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. Trop Med Int Health 2000;5: 898-905.
22. BREUER K, KAPP A, WERFEL T. Urine eosinophil protein X (EPX) is an in vitro parameter of inflammation in atopic dermatitis in the adult age. Allergy 2001;56:780-784.
23. OYMAR K, BJERKNES R. Urinary eosinophil protein X in children with atopic dermatitis: relation to atopy and disease activity. Allergy 2000;55:964-968.
24. PRUSSIN C, METCALFE DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111: S486-S494.
25. LEIFERMAN KM, ACKERMAN SJ, SAMPSON HA, HAUGEN HS, VENENCIE PY, GLEICH GJ. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. N Engl J Med 1985;313:282-285.
26. LEIFERMAN KM, FUJISAWA T, GRAY BH, GLEICH GJ. Extracellular deposition of eosinophil and neutrophil granule proteins in the IgE-mediated cutaneous lete phase reaction. Lab Invest 1990;62:579-589.
27. CHENG JF, OTT NL, PETERSON EA, GEORGE TJ, HUNKEE MJ, GLEICH GJ et al. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol 1997;99: 683-692.
28. LEIFERMAN KM. A role for eosinophils in atopic dermatitis. J Am Acad Dermatol 2001;45:S21-S24.
29. DENBURG JA, TELIZYN S, MESSNER H, LIM B, JAMAL N, ACKERMAN SJ et al. Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood 1985;66:312-318.
30. LINDEN M, SVENSON C, ANDERSSON M, GREIFF L, ANDERSSON E, DENBURG JA et al. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. Allergy 1999;54:212-219.
31. CYR MM, DENBURG JA. Systemic aspects of allergic diseases: the role of the bone marrow. Current Opinion in Immunology 2001;13:727-732.
32. FOSTER P, HOGAN P, RAMSAY AJ, MATTHAEI KI, YOUNG IG. Interleukin-5 deficiency abolishes eosinophilia, airway hyperreactivity and lung damage in a mouse asthma model. J Exp Med 1996;83:195-201.
33. DENT LA, STRATH M, MELLOR AL, SANDERSON CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990;172:1425-1431.
34. NASHINAKAMURA R, MIYAJIMA A, MEE PJ, TYBULEWICZ VLJ, MURRAY R. Hematopooiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 1996;88: 2458-2464.
35. SAITO H, HOWIE K, WATTIE J, DENBURG A, ELLIS R, INMAN MD et al. Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis. Immunology 2001;104:226-234.
36. PALFRAMAN RT, COLLINS PD, SEVERS NJ, ROTHERY S, WILLIAMS TJ, RANKIN SM. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin-5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med 1998;188:1621-1632.
37. PALFRAMAN RT, COLLINS PD, WILLIAMS TJ, RANKIN SM. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 1998;91:2240-2248.
38. BROIDE D, SRIRAMARAO P. Eosinophil trafficking to sites of allergic inflammation. Immunol Rev 2001;179:163-172.
39. BOCHNER BS, CHARLESWORTH EN, LICHTENSTEIN LM. Interleukin-1 is released at sites of human cutaneous allergic reactions. J Allergy Clin Immunol 1990;86:830-839.
40. MULLARKEY M, LEIFERMAN KM, PETERS MS, CARO I, ROUX ER, HANNA RK et al. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 1994;52: 2033-2041.
41. WAKITA H, SAKAMOTO T, TOKURA Y, TAKIGAWA M. E-selectin and vascular adhesion molecule 1 as critical adhesion molecules for infiltration of T lymphocytes and eosinophils in atopic dermatitis. J Cutan Pathol 1993;21:33-39.
42. DOBRINA A, MENEGAZZI R, CARLOS TM, NARDON E, CRAMER R, ZACCHI T et al. Mechanisms of eosinophil adherence to cultured vascular endothelial cells. J Clin Invest 1991;88:20-26.
43. SCHLEIMER RP, STERBINSKY SA, KAISER J, BICKEL CA, KLUNK DA, TOMIOKA K et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 1992;148:1086-1092.
44. MOSER R, FEHR J, BRUIJNZEEL LB. IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J Immunol 1992;149:1432-1438.
45. SCHNYDER B, LUGLI S, FENG N, ETTER H, LUTZ RA, RYFFEL B et al. IL-4 and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular adhesion molecule-1 induction in the absence of the common γ chain. Blood 1996;87:4286-4295.
46. FERNVIK E, HALLDEN G, LUNDAHL J, RAUD J, ALKNER U, VAN HAGE-HAMSTEN M et al. Allergen-induced accumulation of eosinophils and lymphocytes in skin chambers is associated with increased levels of interleukin-4 and sVCAM-1. Allergy 1999;54:455-463.
47. ELSNER J, KAPP A. Regulation and modulation of eosinophil effector functions. Allergy 1999;54:15-26.
48. DISCIPIO R, DAFFERN P, JAGELS MA, BROIDE DH, SRIRAMARAO P. C3a and C5a mediate the rapid activation dependent conversion of rolling eosinophils to firmly adherent eosinophils in vivo. J Immunol 1999;162:1127-1136.
49. TAGER AM, DUFOUR JH, GOODARZI K, BERCURY SD, VON ADRIAN UH, LUSTER AD. BLTR mediates leukotriene (4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med 2000;192:439-446.
50. HIRAI H, TANAKA K, YOSHIE O, OGAWA K, KENMOTSU K, TAKAMORI Y et al. Prostaglandin D2 selectively induces chemotaxis in T-helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-262.
51. BANDEIRA-MELO C, BOZZA PT, DIAS BL, CORDEIRO RS, JOSE PJ, MARTINS MA et al. Lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J Immunol 2000;164:2267-2271.
52. MOCHIZUKI M, BARTELS J, MALLET AI, CHRISTOPHERS E, SCHRÖDER JM. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol 1998;160:60-68.
53. WANG J, HOMER RJ, CHEN Q, ELIAS JA. Endogenous and exogenous IL-6 inhibit aeroallergen-induced Th2 inflammation. J Immunol 2000;165:4051-4061.
54. WANG J, HOMER RJ, HONG L, COHN L, LEE CG, JUNG S et al. IL-11 selectively inhibits aeroallergen-induced pulmonary eosinphilia and Th2 cytokine production. J Immunol 2000;165:2222-2231.
55. ZHAO LL, LINDEN A, SJÖSTRAND M, CUI ZH, LÖTVALL J, JORDANA M. IL-12 regulates bone marrow eosinophilia and airway eotaxin levels induced by airway allergen exposure. Allergy 2000;55:749-756.
56. ROTHENBERG ME, MACLEAN JA, PEARLMAN E, LUSTER AD, LEDER P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997;185:785-790.
57. YING S, TABORDA-BARATE L, MENG Q, HUMBERT M, KAY MB. The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T cell, and macrophage recruitment. J Exp Med 1995;181: 2153-2159.
58. GONZALO JA, LLOYD CM, WEN D, ALBAR JP, WELLS TN, PROUDFOOT A et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998;188:157-167.
59. DOMBROVICZ D, CAPRON M. Eosinophils, allergy and parasites. Current Opin Immunology 2001;13:716-720.
60. SALLUSTO F, MACKAY CR, LANZAVECHIA A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593-620.
61. PONATH PD, QIN S, POST TW, WANG J, WU L, GERARD NP et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996;183: 2349-2354.
62. HOMEY B, ZLOTNIK A. Chemokines in allergy. Curr Opin Immunol 1999; 11:626-634.
63. NAGASE H, YAMAGUCHI M, JIBIKI S, YAMADA H, OHTA K, KAWASAKI H et al. Eosinophil chemotaxis by chemokines: a study by a simple photometric assay. Allergy 1999;54:944-950.
64. HOSSNY E, ABOUL-MAGD M, BAKR S. Increased plasma eotaxin in atopic dermatitis and acute urticaria in infants and children. Allergy 2001;56:996-1002.
65. YAWALKAR N, UGUCCIONI M, SCHÄRER J, BRAUNWALDER J, KARLEN S, DEWALD B et al. Enhanced expression of eotaxin and CCR-3 in atopic dermatitis. J Invest Dermatol 1999;113:43-48.
66. WEILIE M, BRYCE PJ, HUMBLES AA, LAOUINI D, YALCINDAG A, ALENIUS H et al. CCR-3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002;109:621-628.
67. MASUMOTO A, HEMLER ME. Multiple activation states of VLA-4. Mechanistic differences between adhesion to CS-1/fibronectin and to vascular cell adhesion molecule-1. J Biol Chem 1993;268: 228-234.
68. GLEICH GJ. Mechanisms of eosinophil associated inflammation. J Allergy Clin Immunol 2000;105:651-663.
69. MENZIES-GOW A, YING S, SABROE I, STUBBS VL, SOLER D, WILLIAMS T et al. Eotaxin and eotaxin-2 induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002;169:2712-2718.
70. BRUYNZEEL-KOOMEN CAFM, VAN WICHEN DF, SPRY CJF, VENGE P, BRUYNZEEL PLB. Active participation of eosinophils in patch test reactions to inhalant allergens in patients with atopic dermatitis. Br J Dermatol 1988;118: 229-238.
71. MITCHELL EB, CHAPMAN MD, POPE FM, CROW J, JOUHAL SS, PLATTS-MILLS TAE. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1982;i:127-130.
72. WAKUGAWA M, NAKAGAWA H, YAMADA N, TAMAKI K. Chronologic analysis of eosinophil granule protein deposition and cell adhesion molecule expression in mite allergen-induced dermatitis in atopic subjects. Int Arch Allergy Immunol 1996;111:S5-S11.
73. NIGGEMANN B, BEYER K, WAHN U. The role of eosinophils and eosinophil cationic protein in monitoring oral challenge tests in children with food sensitive atopic dermatitis. J Allergy Clin Immunol 1994;94:963-971.
74. SIMON HU. Eosinophil apoptosis in allergic diseases - an emerging new issue. Clin Exp Allergy 1998;28:1321-1324.
75. SIMON HU, YOUSEFI S, SCHRANZ C, SCHAPOWAL A, BACHERT C, BLASER K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902-3908.
76. SIMON HU, BLASER K. Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia? Immunol Today 1995;16:53-55.
77. SIMON HU. Eosinophil apoptosis - pathophysiologic and therapeutic implications. Allergy 2000;55:910-915.
78. SHINAGAWA K, TRIFILIEFF A, ANDERSON GP. Involvement of CCR3-reactive chemokines in eosinophil survival. Int Arch Allergy Immunol 2003;130: 150-157.
79. WEDI B, RAAP U, LEWRICK H, KAPP A. Delayed eosinophil programmed cell death in vitro: a common feature in inhalant allergy and extrinsic and intrinsic dermatitis. J Allergy Clin Immunol 1997;100:536-543.
80. DIBBERT B, DAIGLE I, BRAUN D, SCHRANZ C, WEBER M, BLASER K et al. Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood 1998;92:778-783.
81. PLOETZ SG, DIBBERT B, ABECK D, RING J, SIMON HU. Bcl-2 expression by eosinophils in a patient with hypereosinophilia. J Allergy Clin Immunol 1998;102:1037-1040.
82. OGAWA K, HASHIDA R, MIYAGAWA M, KAGAYA S, SUGITA Y, MATSUMOTO K et al. Analysis of gene expression in peripheral blood eosinophils from patients with atopic dermatitis and in vitro cytokine-stimulated blood eosinophils. Clin Exp Immunol 2003;131: 436-445.
83. WEDI B, RAAP U, KAPP A. Significant delay of apoptosis and Fas resistance in eosinophils of subjects with intrinsic and extrinsic type of atopic dermatitis. Int Arch Allergy Immunol 1999;118: 234-235.
84. HEBESTREIT H, DIBBERT B, BALATTI I, BRAUN D, SCHAPOWAL A, BLASER K et al. Disruption of Fas receptor signaling by nitric oxide in eosinophils. J Exp Med 1998;187:415-425.
85. TAKAFUJI S, BISCHOFF SC, DE WECK AL, DAHINDEN CA. IL-3 and IL-5 prime normal eosinophils to produce leukotriene C4 in response to soluble agonists. J Immunol 1991;147:3855-3861.
86. ROTHENBERG ME, OWEN WF, SILBERSTEIN DS, SOBERMAN RJ, AUSTEN KF, STEVENS RL. Eosinophils cocultured with endothelial cells have increased survival and functional properties. Science 1987;237:645-647.
87. SEHMI R, WARDLAW AJ, CROMWELL O, KURIHARA K, WALTMANN P, KAY AB. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 1992;79:2952-2959.
88. TOMIOKA K, MACGLASHAN DW, LICHTENSTEIN LM, BOCHNER BS, SCHLEIMER RP. GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor. J Immunol 1993;151:4989-4997.
89. DAHINDEN CA, ZINGG J, MALY FE, DE WECK AL. Leukotriene production in human neutrophils primed by recombinant human granulocyte/macrophage colony-stimulating factor and stimulated with the complement component C5a and fMLP as second signals. J Exp Med 1988;167:1281-1295.
90. SIMON HU, PLOETZ S, SIMON D, SEITZER U, BRAATHEN LR, MENZ G et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol 2003;33: 834-839.
91. SIMON HU, WEBER M, BECKER E, ZILBERMAN Y, BLASER K, LEVI-SCHAFFER F. Eosinophils maintain their capacity to signal and release eosinophilic cationic protein upon repetitive stimulation with the same agonist. J Immunol 2000;165:4069-4075.
92. YOUSEFI S, HEMMANN S, WEBER M, HOELZER C, HARTUNG K, BLASER K et al. IL-8 is expressed by human peripheral blood eosinophils. J Immunol 1995;154:5481-5490.
93. SCHMID-GRENDELMEIER P, ALTZNAUER F, FISCHER B, BIZER C, STRAUMANN A, MENZ G et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 2002;169:1021-1027.
94. BOCHNER BS. Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol 2000;106:S292-S302.
95. GOUNNI AS, LAMKHIOUED B, OCHIAI K, TANAKA Y, DELAPORTE E, CAPRON A et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994;367:183-186.
96. SEMINARIO MC, SAINI SS, MACGLASHAN DW, BOCHNER BS. Intracellular expression and release of FcεRIa by human eosinophils. J Immunol 1999;162: 6893-6900.
97. KITA H, KANEKO M, BARTEMES KR, WEILER DA, SCHIMMING AW, REED CE et al. Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 1999;162:6901-6911.
98. BANDEIRA-MELO C, SUGIYAMA K, WOODS LJ, WELLER PF. Eotaxin elicits rapid vesicular transport-mediated release of preformed IL-4 from human eosinophils. J Immunol 2001;166: 4813-4817.
99. WOERLY G, ROGER N, LOISEAU S, DOMBROWICZ D, CAPRON A, CAPRON M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (Interleukin 2 and interferon-gamma): inhibition by immunoglobulin A complexes. J Exp Med 1999;190:487-495.
100. BANDEIRA-MELO C, BOZZA PT, WELLER PF. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 2002;109: 393-400.
101. SCHAUER U, TRUBE M, JAGER R, GIELER U, RIEGER CH. Blood eosinophils, eosinophil-derived proteins, and leukotriene C4 generation in relation to bronchial hyperreactivity in children with atopic dermatitis. Allergy 1995;50:126-132.
102. SANAK M, SIMON HU, SZCZEKLIK A. LEUKOTRIENE C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350: 1599-1600.
103. MAWHORTER SD, KAZURA JW, BOOM WH. Human eosinophils as antigen-presenting cells: relative efficacy for superantigen- and antigen-induced CD4+ T-cell proliferation. Immunology 1994;81:584-591.
104. MORI A, SUKO M, NISHIZAKI Y, KAMINUMA O, MATSUZAKI G, ITO K et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. Int Arch Allergy Immunol 1994;104:S32-S35.
105. MORI A, KAMINUMA O, SUKO M, INOUE S, OHMURA T, HOSHINO A et al. Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Blood 1997;89:2891-2900.
106. MEAGHER LC, COUSIN JM, SECKL JR, HASLETT C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-4428.
107. OEHLING AG, AKDIS CA, SCHAPOWAL A, BLASER K, SCHMITZ M, SIMON HU. Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy 1997;52:144-154.
108. BARNES PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 2001;56:928-936.
109. HEATON T, MALLON D, VENAILLE T, HOLT P. Staphylococcal enterotoxin induced IL-5 stimulation as a cofactor in the pathogenesis of atopic disease: the hygiene hypothesis in reverse? Allergy 2003;58:252-256.
110. SIMON D, CONUS S, VASSINA E, BRAATHEN LR, SIMON HU. Immunopharmacological effects of topical tacrolimus in atopic dermatitis. J Eur Acad Derm Venerol 2003;17:S156.
111. NOH GW, LEE KY. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 1998;53:1202-1207.
112. BREUCKMANN F, VON KOBYLETZKI G, AVERMAETE A, PIECK C, KREUTER A, BROCKMEYER NH et al. Mononuclear cells in atopic dermatitis in vivo: immunomodulation of the cutaneous infiltrate by medium-dose UVA1 phototherapy. Eur J Med Res 2002;7:315-322.
113. SIMON HU. The neutralization of Interleukin-5 as a therapeutic concept in allergic inflammation. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:25-28.
114. HAMELMANN E, OSHIBA A, LOADER J, LARSEN GL, GLEICH G, LEE J et al. Anti-interleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitisation. Am J Respir Crit Care Med 1997;155:819-825.
115. LECKIE MJ, TEN BRINKE A, KHAN J, DIAMANT Z, O'CONNOR BJ, WALLS CM et al. Effects of an interleukin-5 blocking antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
116. PLOETZ SG, SIMON HU, DARSOW U, SIMON D, VASSINA E, YOUSEFI S et al. Use of anti-interleukin-5 antibody in hypereosinophilic syndrome with eosinophilic dermatitis. N Eng J Med 2003;349:2332-2337.